Application of Amurensin H derivative EAPP in treatment and prevention of aplastic anemia

An aplastic, derivative technology, applied in the field of biomedicine

Active Publication Date: 2020-05-05
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

And the application of this compound in the treatment and / or prevention of aplastic anemia has not yet been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Amurensin H derivative EAPP in treatment and prevention of aplastic anemia
  • Application of Amurensin H derivative EAPP in treatment and prevention of aplastic anemia
  • Application of Amurensin H derivative EAPP in treatment and prevention of aplastic anemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1: Preparation of compound (I) [3-(3,5-dimethoxyphenyl)-6-methoxy-4-benzofurancarboxylic acid-4-acetylphenyl ester].

[0051] The synthetic steps of compound EAPP (I) are as follows:

[0052] Step 1: Synthesis of α-phenoxyketocarboxylic acid through etherification reaction between methyl 3-methoxy-5-hydroxybenzoate and 1-(3,5-dimethoxyphenyl)-2-bromoacetophenone methyl ester.

[0053] Methyl 3-methoxy-5-hydroxybenzoate (4.5g, 26.8mmol) was dissolved in 1-(3,5-dimethoxyphenyl)-2-bromoacetophenone (6.94g, 26.8mmol) In 150ml of dry acetone, slowly add K under vigorous stirring 2 CO 3 The solid was 7.39g (53.5mmol), and the reaction solution was stirred at room temperature for 3h, and then heated to reflux for 3h. TLC monitoring showed that the reaction of raw materials was complete. The reaction solution was cooled to room temperature, filtered with diatomaceous earth, washed with acetone, and the organic phase was concentrated under reduced pressure. The resu...

experiment example 1

[0065] Experimental example 1: The effect of EAPP on aplastic anemia mouse model

[0066] experimental method:

[0067] Get male BALB / c mouse of 18-20g, divide into normal control group, model control group, positive control group (cyclosporine 10mg / kg, intragastric administration) at random, EAPP group (5mg / kg, 10mg / kg, 20mg / kg, intragastric administration). In addition to the blank control group, the animals in each group were inoculated intravenously with cobalt-60γ rays (5.80Gy cobalt-60γ rays for one whole body irradiation) + DBA / 2 mouse thymus:spleen immune cells (2:1) to prepare aplastic anemia models ; From the day of modeling, intragastric administration, once a day, for 14 consecutive days. One hour after the last administration, blood was collected from the orbital vein of the mice, and EDTA-K 2 Anticoagulation, five-differential blood cell analyzer to detect blood routine and flow cytometry to detect reticulocyte count; remove the thymus and spleen of the mouse,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of an Amurensin H derivative EAPP shown in a formula (I) in preparation of products for treating and / or preventing aplastic anemia. The Amurensin H derivative EAPPdisclosed by the invention is simple in preparation method, has obvious anti-inflammatory activity, has a remarkable treatment effect on the aplastic anemia, can be applied to clinical treatment of the aplastic anemia in a form of a monomer or a medicinal composition, and has potential application value in treatment of the aplastic anemia and immune-related diseases.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular to an Amurensin H derivative EAPP or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the derivative or a pharmaceutically acceptable salt thereof. Application in aplastic anemia. Background technique [0002] Aplastic anemia (referred to as aplastic anemia, AA) is a relatively serious blood system disease caused by chemical, physical, biological factors or other unknown reasons, characterized by pancytopenia caused by bone marrow hematopoietic failure, The main clinical manifestations are anemia, bleeding and infection, which can be life-threatening. Its etiology and pathogenesis are very complex, and it is currently believed to be related to hematopoietic stem / progenitor cell defects, abnormal bone marrow hematopoietic microenvironment, and bone marrow hematopoietic suppression mediated by immune disorders. Among them, the key role of imm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/343A61P7/06
CPCA61K31/343A61P7/06Y02A50/30
Inventor 林明宝姚春所侯琦张梓倩李姝仪朱其彬滕彬豪
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap